Revolution Medicines' experimental oral drug helped patients with pancreatic cancer live longer and showed an improvement in survival without worsening of the disease in a keenly anticipated late-stage trial. Patients who received the once-daily pill, daraxonrasib, showed a median overall survival of 13.2 months compared with 6.7 months for those who were given intravenous cytotoxic chemotherapy, the standard of care, the company said on Monday.
Experimental pancreatic cancer pill helps improve survival in late-stage study
Political Leaning Analysis
Score: 0.00 •
Center / Neutral
Left
Center
Right
Story Timeline
Tue 11:53 - The Hill
Pancreatic cancer pill shown to nearly double overall survival time, drug company says
Wed 12:53 - France 24
Experimental pancreatic cancer pill helps improve survival in late-stage study